Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenkun Ma

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Plos One|September 24, 2015
G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell CarcinomaFeng Li, Jin Zeng, Yang Gao, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2011
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulationYu Lu, Meiqin Zheng, Bin Wang, et al.
Oncology Reports|September 2, 2015
Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinomaZhenkun Ma, Wei Liu, Jin Zeng, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Synthesis and antibacterial activity of novel bifunctional macrolidesIrini Akritopoulou-Zanze, Kathleen M Phelan, Thomas G Marron, et al.
Oncotarget|December 29, 2016
Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancerBing Guan, Kaijie Wu, Jin Zeng, et al.
Oncology Reports|October 2, 2018
Silibinin attenuates TGF‑β1‑induced migration and invasion via EMT suppression and is associated with COX‑2 downregulation in bladder transitional cell carcinomaFeng Li, Yi Sun, Jing Jia, et al.
Oncotarget|March 14, 2022
Correction: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancerBing Guan, Kaijie Wu, Jin Zeng, et al.
The Lancet. Infectious Diseases|February 15, 2024
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsXiaojiao Li, Yusi Liu, Meng Wang, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2006
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferasesKeith D Combrink, Daniel A Denton, Susan Harran, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Plos One|September 24, 2015
G9a Inhibition Induces Autophagic Cell Death via AMPK/mTOR Pathway in Bladder Transitional Cell CarcinomaFeng Li, Jin Zeng, Yang Gao, et al.
Expert Opinion on Investigational Drugs|January 22, 2026
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drugMengdi Lu, Jing Chen, Hong Zhang, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2011
Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulationYu Lu, Meiqin Zheng, Bin Wang, et al.
Oncology Reports|September 2, 2015
Silibinin induces apoptosis through inhibition of the mTOR-GLI1-BCL2 pathway in renal cell carcinomaZhenkun Ma, Wei Liu, Jin Zeng, et al.
Bioorganic & Medicinal Chemistry Letters|June 19, 2004
Synthesis and antibacterial activity of novel bifunctional macrolidesIrini Akritopoulou-Zanze, Kathleen M Phelan, Thomas G Marron, et al.
Oncotarget|December 29, 2016
Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancerBing Guan, Kaijie Wu, Jin Zeng, et al.
Oncology Reports|October 2, 2018
Silibinin attenuates TGF‑β1‑induced migration and invasion via EMT suppression and is associated with COX‑2 downregulation in bladder transitional cell carcinomaFeng Li, Yi Sun, Jing Jia, et al.
Oncotarget|March 14, 2022
Correction: Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancerBing Guan, Kaijie Wu, Jin Zeng, et al.
The Lancet. Infectious Diseases|February 15, 2024
Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trialsXiaojiao Li, Yusi Liu, Meng Wang, et al.
Bioorganic & Medicinal Chemistry Letters|October 31, 2006
New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferasesKeith D Combrink, Daniel A Denton, Susan Harran, et al.
Pageof 7